BioCardia, Inc.
- Open
- 1.14
- Day high
- 1.16
- Day low
- 1.10
- Prev close
- 1.15
- Volume
- 141K
- Mkt cap
- $17M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 6.4
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $136K over the last 3 months (14 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
- 🏛Institutions reducing (13F)
BioCardia, Inc. (BCDA) is a Healthcare company listed on NASDAQ. The stock is down 43% over the past year. Over the trailing 3 months, insiders filed 14 open-market buys and 0 sales (SEC Form 4). Drillr has 3 published research articles covering BCDA.
BioCardia, Inc. (BCDA) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
BCDA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 12, 2026 | $-0.18 | $-0.13 | +27.8% | — | — |
| May 15, 2026 | $-0.17 | $-0.21 | -23.5% | — | — |
| Mar 24, 2026 | $-0.20 | $-0.06 | +70.0% | — | — |
| Nov 12, 2025 | $-0.25 | $-0.24 | +4.0% | — | — |
| May 14, 2025 | $-0.39 | $-0.59 | -51.3% | — | — |
| Mar 26, 2025 | $-0.87 | $-0.25 | +71.3% | $25000 | +11.1% |
| Nov 13, 2024 | $-1.19 | $-0.61 | +48.7% | $58000 | +190.0% |
| Aug 13, 2024 | $-0.10 | $-0.88 | -780.0% | $3000 | -94.0% |
| Nov 9, 2022 | $-3.45 | $-2.55 | +26.1% | $212000 | +87.6% |
| Aug 10, 2022 | $-4.20 | $-2.10 | +50.0% | $974000 | +958.7% |
| Nov 10, 2021 | $-0.21 | $-2.40 | -1042.9% | $821000 | — |
| Aug 12, 2021 | $-3.15 | $-3.00 | +4.8% | $69000 | +0.0% |
BCDA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 18, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 5,400 | $0.93 |
| Aug 13, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 1,900 | $0.92 |
| Jul 29, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 5,000 | $0.78 |
| Jul 20, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 500 | $0.83 |
| Jul 15, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 2,800 | $0.88 |
| Jul 15, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 1,500 | $0.86 |
| Jul 10, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 5,500 | $0.97 |
| Jul 10, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 1,000 | $0.90 |
| Jul 8, 2026 | Altman Peterdirector, officer: President and CEO | Buy | 5,400 | $0.96 |
| Jul 7, 2026 | GILLIS EDWARD Mofficer: Senior Vice President, Devices | Tax | 17,269 | $1.24 |
| Jul 7, 2026 | McClung Davidofficer: Chief Financial Officer | Grant | 41,501 | $1.20 |
| Jul 7, 2026 | Blank Andrew Scottdirector | Grant | 8,000 | $1.20 |
| Jul 7, 2026 | Altman Peterdirector, officer: President and CEO | Tax | 54,606 | $1.24 |
| Jul 7, 2026 | Facteau Billdirector | Grant | 8,000 | $1.20 |
| Jul 7, 2026 | MOYES JAY Mdirector | Grant | 8,000 | $1.20 |
Source: BCDA SEC Form 4 filings, latest Aug 18, 2026. For informational purposes only — not investment advice.
See the full BCDA insider & 13F page →BCDA research & analysis
BioCardia (BCDA), Cuorips (4894.T): Japan Prices Cardiac Cell Therapy
Japan's conditional approval pathway set a ¥53.2 million reimbursed price for ReHeart, making MHLW the first regulator to price cardiac cell therapy.
219A.T4593.T4894.TFDA Drops Sham Control for Rare-Disease Gene Therapy (CLPT, QURE)
The FDA told uniQure a sham-surgery control is no longer required, moving the cost of rare-disease gene therapy onto delivery hardware and endpoint instruments.
BIIBCLPTDNLIuniQure (QURE), ClearPoint (CLPT): FDA Drops Sham-Surgery Control
uniQure, ClearPoint and BioCardia disclosed the FDA no longer requires a sham-surgery control in rare CNS gene therapy, moving the gate to delivery hardware.
CLPTCYRXMGTX
BioCardia, Inc. company profile
Overview
BioCardia, Inc. (NASDAQ:BCDA) is a clinical-stage regenerative medicine company founded in 1996 and headquartered in Sunnyvale, California. The company develops cellular and cell-derived therapeutics primarily targeting cardiovascular and pulmonary diseases. BioCardia operates as a biotechnology company focused on advancing multiple therapeutic platforms through clinical trials, with particular emphasis on cell therapy treatments for heart failure and chronic myocardial ischemia. The company has been publicly traded since its IPO in November 1996 and currently maintains a small market capitalization as it progresses through various phases of clinical development.
Business
BioCardia operates in the regenerative medicine sector within biotechnology, developing treatments that use cellular therapies to repair or regenerate damaged heart and lung tissue. The company's approach centers on using stem cells and specialized delivery systems to treat cardiovascular diseases where traditional treatments have limited effectiveness. The company's primary therapeutic platforms include: 1. **CardiAMP Cell Therapy System** - This is BioCardia's lead therapeutic candidate, which uses autologous (patient's own) bone marrow-derived cells to treat heart failure and chronic myocardial ischemia. The system involves harvesting a patient's bone marrow cells, processing them to concentrate therapeutic cells, and then delivering them directly into damaged heart muscle tissue. This approach aims to stimulate the heart's natural healing processes and improve cardiac function. 2. **CardiALLO Allogeneic Cell Therapy** - This platform uses donor-derived mesenchymal stem cells rather than the patient's own cells. These are culture-expanded bone marrow-derived cells that can be manufactured in advance and used across multiple patients, potentially offering advantages in terms of availability and standardization compared to autologous treatments. 3. **Helix Biotherapeutic Delivery System** - This is a specialized medical device that delivers therapeutics directly into heart muscle using a penetrating helical needle from within the heart. This delivery system is designed to ensure that therapeutic cells or other treatments reach the precise location where they are needed most effectively. 4. **Morph DNA Steerable Introducer Platform** - This consists of deflectable guides and sheaths that help physicians navigate and position medical devices within the cardiovascular system during procedures. The platform has received FDA approval for multiple configurations and represents a more immediately commercializable product line. The company generates minimal revenue currently, as most products remain in clinical development phases, with the Morph platform representing the primary near-term revenue opportunity.
Revenue model
BioCardia's business model is currently focused on clinical development rather than commercial revenue generation. The company operates primarily as a research and development entity, funding operations through equity financing while advancing its therapeutic candidates through clinical trials toward regulatory approval and eventual commercialization. **Current Revenue Sources:** The company generates minimal revenue, with only $58,000 in total revenue for 2024, primarily from research collaborations or licensing activities. This represents a significant decrease from $477,000 in 2023, indicating the company is not yet in commercial operations. **Future Revenue Model:** BioCardia's intended revenue streams include: 1. **Product Sales** - Direct sales of approved cell therapies and medical devices, particularly the Morph DNA platform which has already received FDA approval for 16 product configurations. 2. **Licensing and Partnerships** - The company is actively pursuing partnership agreements across all four platforms, which could generate upfront payments, milestone payments, and royalties. Management has indicated ongoing discussions for potential partnerships in Japan, Brazil, and UAE markets. 3. **Service Fees** - Potential treatment administration fees for cell therapy procedures performed at medical centers. **Factors Affecting Profitability:** The company's path to profitability faces several challenges. **Positive factors** include the potential for high-margin cell therapy treatments, which can command premium pricing due to their specialized nature and limited competition. The company's focus on personalized medicine and the significant unmet medical need in heart failure treatment could support value-based pricing strategies. **Negative factors** include the substantial ongoing clinical trial costs, which consumed $4.4 million in R&D expenses in 2024. The company faces regulatory uncertainty, as approval timelines with the FDA and international regulators like Japan's PMDA remain unpredictable. Additionally, the company operates in a capital-intensive industry requiring continuous funding for clinical development, and competition from larger pharmaceutical companies with greater resources poses ongoing challenges. Manufacturing and scaling cell therapy treatments also present complex logistical and cost challenges that could impact future margins.
Competitive moat
BioCardia's competitive positioning reflects the early-stage nature of the regenerative medicine industry, where sustainable competitive advantages are still developing. The company's potential moat elements are primarily based on **intellectual property, regulatory barriers, and specialized expertise** rather than traditional business moats. **Potential Moat Elements:** The company's **Helix biotherapeutic delivery system** represents a unique approach to delivering therapeutics directly into heart muscle tissue, which could provide procedural advantages over competing delivery methods. The **Morph DNA steerable introducer platform** has received FDA approval for multiple configurations and includes proprietary rotating tendon technology that management claims provides competitive advantages in cardiac electrophysiology procedures. BioCardia's **clinical data and regulatory pathway progress** could create temporary competitive advantages, particularly in Japan where the company is pursuing approval based on U.S. clinical trial data. The specialized knowledge and relationships developed through years of clinical trials in cardiovascular cell therapy represent institutional knowledge that would be difficult for new entrants to replicate quickly. **Moat Limitations:** However, BioCardia's moat is relatively **weak** compared to established pharmaceutical companies. The company lacks the financial resources, manufacturing scale, and commercial infrastructure of larger competitors. The regenerative medicine field attracts significant investment from major pharmaceutical companies and well-funded biotechnology firms, many of which have greater resources to advance competing therapies. **Competitive Threats:** The primary competitive risks come from **larger pharmaceutical companies** developing alternative cell therapy approaches, **medical device companies** creating competing delivery systems, and **well-funded biotech companies** pursuing similar regenerative medicine targets. Additionally, the company faces the risk that traditional pharmaceutical treatments or other medical interventions could prove more effective or easier to commercialize than cell-based therapies. The company's small size and limited financial resources make it vulnerable to being outpaced by competitors with greater capital and development capabilities, suggesting that partnerships or acquisition may be necessary for long-term competitive viability.
Risks & safety
BioCardia presents **significant financial risk** with minimal margin of safety for investors, reflecting the precarious financial position typical of clinical-stage biotechnology companies. **Cash and Liquidity Crisis:** - Cash position of only $949,000 as of Q1 2025, down from $2.4 million at end of 2024 - Quarterly cash burn of approximately $1.6 million in Q1 2025 - Current ratio of 0.36, indicating inability to meet short-term obligations - Working capital deficit of over $2 million **Debt and Solvency:** - Total liabilities of $3.7 million exceed total assets of $2.2 million - Negative shareholders' equity of approximately $1.5 million - Company requires immediate financing to continue operations beyond next few months **Valuation Concerns:** - No meaningful revenue ($58,000 annually) to support current market capitalization - Negative earnings make traditional valuation metrics irrelevant - Stock price has declined significantly from historical levels (traded over $89 in 2022, now around $2.77) **Other Risk Factors:** - Clinical trial outcomes remain uncertain with binary success/failure scenarios - Regulatory approval timelines unpredictable and potentially years away - NASDAQ delisting risk due to non-compliance with listing requirements - Dependence on equity financing in challenging biotech funding environment
Recent development
Over the past few years, BioCardia has made significant strategic progress in advancing its clinical programs while simultaneously exploring partnership opportunities to monetize its technology platforms. **Clinical Trial Advancement:** The company's most significant development has been the **CardiAMP Heart Failure trial results**, which showed compelling efficacy signals including a 47% relative risk reduction in heart death equivalents and meaningful improvements in quality of life measures. These results have enabled the company to initiate the **CardiAMP Heart Failure II confirmatory trial**, a 250-patient pivotal study that received FDA approval for protocol amendments to personalize treatment and increase patient eligibility by approximately 85%. **Regulatory Progress:** BioCardia has made substantial progress with **international regulatory pathways**, particularly in Japan where the company has engaged with the PMDA (Pharmaceuticals and Medical Devices Agency) for potential approval based on U.S. clinical data. This represents a significant strategic opportunity, as Japan's regulatory environment may provide a faster pathway to approval compared to the FDA process. **Platform Diversification:** The company has successfully developed its **Morph DNA steerable introducer platform**, receiving FDA approval for 16 product configurations. This platform represents the most near-term commercialization opportunity and has generated active partnership discussions in the cardiac electrophysiology market. **Business Development Focus:** Management has shifted toward a **partnership-focused strategy** across all four platforms (CardiAMP, CardiALLO, Helix, and Morph DNA), recognizing the need for external capital and commercial expertise to fully develop and market these technologies. The company is actively pursuing distribution partnerships in multiple international markets including Japan, Brazil, and the UAE. **Operational Efficiency:** The company has demonstrated **improved cost management**, reducing total expenses by 35% year-over-year in 2024 to $8.1 million, with R&D expenses decreasing 43% to $4.4 million while maintaining clinical trial momentum.
BCDA company profile · for informational purposes only — not investment advice.
Track BCDA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free